354 related articles for article (PubMed ID: 16273638)
81. Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption.
Choi HJ; Ku JK; Kim MY; Kang H; Cho SH; Kim HO; Park YM
Br J Dermatol; 2006 Mar; 154(3):419-25. PubMed ID: 16445769
[TBL] [Abstract][Full Text] [Related]
82. Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response.
Abrams SI
Front Biosci; 2005 Jan; 10():809-21. PubMed ID: 15569621
[TBL] [Abstract][Full Text] [Related]
83. Fas and Fas-ligand expression in human pancreatic cancer.
Kornmann M; Ishiwata T; Kleeff J; Beger HG; Korc M
Ann Surg; 2000 Mar; 231(3):368-79. PubMed ID: 10714630
[TBL] [Abstract][Full Text] [Related]
84. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia.
Kitagawa M; Yamaguchi S; Takahashi M; Tanizawa T; Hirokawa K; Kamiyama R
Leukemia; 1998 Apr; 12(4):486-92. PubMed ID: 9557605
[TBL] [Abstract][Full Text] [Related]
85. Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer.
Sheehan KM; O'Donovan DG; Fitzmaurice G; O'Grady A; O'Donoghue DP; Sheahan K; Byrne MF; Conroy RM; Kay EW; Murray FE
Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):375-80. PubMed ID: 12655257
[TBL] [Abstract][Full Text] [Related]
86. Apoptosis in the intestinal mucosa of patients with inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways.
Souza HS; Tortori CJ; Castelo-Branco MT; Carvalho AT; Margallo VS; Delgado CF; Dines I; Elia CC
Int J Colorectal Dis; 2005 May; 20(3):277-86. PubMed ID: 15503066
[TBL] [Abstract][Full Text] [Related]
87. Human colon cancer cells express the functional Fas ligand.
Ding EX; Hizuta A; Morimoto Y; Tanida T; Hongo T; Ishii T; Yamano T; Fujiwara T; Iwagaki H; Tanaka N
Res Commun Mol Pathol Pharmacol; 1998 Jul; 101(1):13-24. PubMed ID: 9755840
[TBL] [Abstract][Full Text] [Related]
88. Suppression of FasL expression in tumor cells and preventing tumor necrosis factor-induced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells.
Zhang J; Xu G
Cancer Genet Cytogenet; 2007 Dec; 179(2):112-7. PubMed ID: 18036397
[TBL] [Abstract][Full Text] [Related]
89. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas.
Mann B; Gratchev A; Böhm C; Hanski ML; Foss HD; Demel G; Trojanek B; Schmidt-Wolf I; Stein H; Riecken EO; Buhr HJ; Hanski C
Br J Cancer; 1999 Mar; 79(7-8):1262-9. PubMed ID: 10098769
[TBL] [Abstract][Full Text] [Related]
90. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Suzuki N; Ichino M; Mihara S; Kaneko S; Sakane T
Arthritis Rheum; 1998 Feb; 41(2):344-53. PubMed ID: 9485093
[TBL] [Abstract][Full Text] [Related]
91. Functional expression of Fas and Fas ligand on human intestinal intraepithelial lymphocytes.
Morimoto Y; Hizuta A; Ding EX; Ishii T; Hongo T; Fujiwara T; Iwagaki H; Tanaka N
Clin Exp Immunol; 1999 Apr; 116(1):84-9. PubMed ID: 10209509
[TBL] [Abstract][Full Text] [Related]
92. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis.
Osaki M; Kase S; Kodani I; Watanabe M; Adachi H; Ito H
Gastric Cancer; 2001; 4(4):198-205. PubMed ID: 11846063
[TBL] [Abstract][Full Text] [Related]
93. NF-kappa B-dependent Fas ligand expression.
Hsu SC; Gavrilin MA; Lee HH; Wu CC; Han SH; Lai MZ
Eur J Immunol; 1999 Sep; 29(9):2948-56. PubMed ID: 10508269
[TBL] [Abstract][Full Text] [Related]
94. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.
Houston A; Bennett MW; O'Sullivan GC; Shanahan F; O'Connell J
Br J Cancer; 2003 Oct; 89(7):1345-51. PubMed ID: 14520470
[TBL] [Abstract][Full Text] [Related]
95. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
96. Fas, ceramide and serum withdrawal induce apoptosis via a common pathway in a type II Jurkat cell line.
Caricchio R; D'Adamio L; Cohen PL
Cell Death Differ; 2002 May; 9(5):574-80. PubMed ID: 11973615
[TBL] [Abstract][Full Text] [Related]
97. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients.
Buzyn A; Petit F; Ostankovitch M; Figueiredo S; Varet B; Guillet JG; Ameisen JC; Estaquier J
Blood; 1999 Nov; 94(9):3135-40. PubMed ID: 10556200
[TBL] [Abstract][Full Text] [Related]
98. Expression of Fas-Fas ligand system associated with atresia in murine ovary.
Xu JP; Li X; Mori E; Sato E; Saito S; Guo MW; Mori T
Zygote; 1997 Nov; 5(4):321-7. PubMed ID: 9563680
[TBL] [Abstract][Full Text] [Related]
99. CC531s colon carcinoma cells induce apoptosis in rat hepatic endothelial cells by the Fas/FasL-mediated pathway.
Vekemans K; Timmers M; Vermijlen D; De Zanger R; Wisse E; Braet F
Liver Int; 2003 Aug; 23(4):283-93. PubMed ID: 12895269
[TBL] [Abstract][Full Text] [Related]
100. Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes.
Li M; Liu X; Zhou S; Li P; Li G
BMC Cancer; 2005 Aug; 5():96. PubMed ID: 16080799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
